Drugs / AdHER2DC vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06253494 | May 2024 → Dec 2026 expected | endometrial carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdHER2DC vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06253494 ↗ |
| Modality | Vaccine | “AdHER2DC vaccine” NCT06253494 ↗ |